Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) announced the appointment of Dr. Sophia N. Ononye-Onyia to its Board of Directors. Dr. Ononye-Onyia brings extensive experience in women's health commercialization, having held senior roles in global biopharmaceutical companies. Her leadership is expected to guide Daré's product candidates, including DARE-BV1, towards successful market entry. Dr. Ononye-Onyia is the founder of The Sophia Consulting Firm and has a strong background in medicinal chemistry and public health. This strategic appointment aims to enhance shareholder value.
Daré Bioscience (NASDAQ: DARE) reported its financial results for the year ending December 31, 2020. The company achieved a commercial partnership with Bayer for Ovaprene, potentially bringing in up to $310 million in milestone payments. The completion of its first Phase 3 study for DARE-BV1 showed a 76% clinical cure rate for bacterial vaginosis. Financially, the company reported a comprehensive loss of $27.4 million, with significant increases in R&D expenses. Cash equivalents were $4.7 million, with $29.5 million in net cash received during FY2020. Future objectives include NDA submissions and ongoing clinical trials.
Daré Bioscience Initiates Phase 2b RESPOND Study
On March 24, 2021, Daré Bioscience (NASDAQ:DARE) announced the start of the Phase 2b RESPOND clinical study for Sildenafil Cream, 3.6%, targeting female sexual arousal disorder (FSAD). This topical formulation of sildenafil aims to directly enhance blood flow to the genital area, potentially becoming the first FDA-approved treatment for FSAD. The study will involve approximately 400 to 590 subjects and aims for topline data by year-end 2021. FSAD affects around 10 million U.S. women, highlighting a significant market opportunity.
Daré Bioscience (NASDAQ: DARE) announced a conference call on March 30, 2021, at 4:30 p.m. ET to discuss its year-end financial results for 2020 and provide company updates. Interested participants can access the call via phone or live webcast on the company's investor relations website. Daré focuses on women's health, developing innovative products including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, aimed at enhancing treatment options in contraception and women’s health.
Daré Bioscience (NASDAQ: DARE) announced the completion of patient recruitment for its Phase 1 clinical trial of DARE-HRT1, an intravaginal ring designed to deliver bio-identical hormones for menopause treatment. The trial aims to assess pharmacokinetics and safety in approximately 30 post-menopausal women. Topline data is expected in Q2 2021. This study could position DARE-HRT1 as a first-in-category product, offering a novel option for hormone therapy. The company plans to utilize existing safety data for regulatory approval through the FDA’s 505(b)(2) pathway.
Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in two virtual conferences: the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17-18, 2021, with presentations available on-demand, and BIO-Europe Spring Digital from March 22-25, 2021. Following the M Vest conference, a webcast will be accessible for two weeks via the company's investor relations website.
Daré focuses on innovative women's health products, including unique therapies for contraception and sexual health.
Daré Bioscience, Inc. (NASDAQ: DARE) announces that President and CEO Sabrina Martucci Johnson will participate in a panel on 'Women’s Health Companies Blazing the Trail' at the 33rd Annual Roth Conference from March 15-17, 2021. The panel discussion will highlight innovations in women's health. A webcast will be available on March 15, 2021, at 5:00 PM ET on their website, remaining accessible until March 29, 2021. Daré focuses on developing therapies for contraception, vaginal health, sexual health, and fertility.
Daré Bioscience, a leader in women's health innovation, will have its CEO, Sabrina Martucci Johnson, present at the H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. The presentation will be accessible starting March 9, 2021, at 7:00 AM EST on the company's website. Daré Bioscience focuses on developing innovative therapies for women's health, including products for contraception, sexual health, and hormone replacement therapy. Key candidates in their pipeline include Ovaprene and Sildenafil Cream for female sexual arousal disorder.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will join a panel at the Maxim Group's Late Stage Innovations in Women’s Health event on March 4, 2021, at 11:00 am ET. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group. The event aims to highlight advancements in women's health innovation. Daré focuses on developing products that enhance women's health, with multiple candidates in its pipeline, including Ovaprene® and Sildenafil Cream, 3.6%.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will participate in a live panel discussion titled The Evolution of Birth Control on February 23, 2021, at 12:30 p.m. EST during the Women’s Health Innovation Series: Contraception Innovation Summit. The discussion will explore innovation challenges in birth control. Ms. Johnson will highlight Daré's commitment to women's health and the development of three innovative contraceptive candidates: Ovaprene®, DARE-LARC1, and ORB formulations. This virtual summit aims to enhance women's contraceptive experiences, featuring stakeholders from various sectors.